Pfizer pays $2.3B penalty for off-label drug marketing

Pfizer has agreed to pay a mammoth $3.2 billion penalty for marketing off-label uses of several of its drugs, a settlement which the U.S. Department of Justice has labeled the largest healthcare fraud settlement in the country's history.

Drugs named in the settlement, included painkiller Bextra, which has been off the market since 2005 in the wake of potential heart risks; antipsychotic Geodon; antibiotic Zyvox; and anti-epileptic drug Lyrica.

In addition to the financial penalty, Pfizer has agreed to an extensive corporate integrity agreement with HHS's Office of the Inspector General, establishing procedures and reviews that are designed to prevent further occurrences of the problem.

The suit springs from a series of whistleblower suits filed under the False Claims Act. As part of the resolution of this case, six whistleblowers are to receive payments of more than $201 million from the federal share of the fines.

To learn more about the case:
- read this U.S. DoJ press release

Related Articles:
Feds indict Synthes over off-label promotions
Pfizer sued over off-label use of Lipitor

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.